Clinical trial · Observational
A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223
NCT03563014CI-TRIAL-00045191BELFIGOcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this non interventional study is to describe the proportion of Belgian mCRPC patients which were treated with 1 to 4 and 5 to 6 Radium-223 injections and the patient characteristics which are potentially associated with this proportion.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostatic Neoplasms, Castration-Resistant | Prostate Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radium-223 (Xofigo, Bay88-8223) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Radium-223 (Xofigo, Bay88-8223)
- description
- Belgium patients with a diagnosis of mCRPC (no known visceral metastases) and who were treated with Radium-223 for this indication
- interventionNames
- Drug: Radium-223 (Xofigo, Bay88-8223)
Primary outcomes (1)
- measure
- The proportion of patients with 5-6 Radium-223 injections versus 1-4 Radium-223 injections
- timeFrame
- Retrospectively analysis from 22 December 2013 to 01 June 2018
Secondary outcomes (13)
- measure
- The proportion of patients with 5-6 Radium-223 injections versus 1-4 Radium-223 injections by Radium-223 line of treatment (1st, 2nd and further line)
- timeFrame
- Retrospectively analysis from 22 December 2013 to 01 June 2018
- measure
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: * Patients with a diagnosis of castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases * All consecutive patients who started Radium-223 treatment between 22 December 2014 and 01 June 2017 * Availability of medical records during the observation period (22DEC2013 - 01JUN2018) Exclusion Criteria: * Patients treated with Radium-223 for any reason before 22 December 2014 (for example an interventional trial) * Patients participated in an investigational program with interventions outside of routine clinical practice during the radium-223 treatment period * Patients received other radiopharmaceuticals for the systemic concomitant use for treatment of prostate cancer or for other use during the Radium-223 treatment period
References
Publications (0)
Data not yet available
No reference posted for this study.